1. Home
  2. STOK vs GETY Comparison

STOK vs GETY Comparison

Compare STOK & GETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • GETY
  • Stock Information
  • Founded
  • STOK 2014
  • GETY 1995
  • Country
  • STOK United States
  • GETY United States
  • Employees
  • STOK N/A
  • GETY N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • GETY Industrial Machinery/Components
  • Sector
  • STOK Health Care
  • GETY Industrials
  • Exchange
  • STOK Nasdaq
  • GETY Nasdaq
  • Market Cap
  • STOK 740.9M
  • GETY 723.5M
  • IPO Year
  • STOK 2019
  • GETY N/A
  • Fundamental
  • Price
  • STOK $12.87
  • GETY $1.79
  • Analyst Decision
  • STOK Strong Buy
  • GETY Hold
  • Analyst Count
  • STOK 5
  • GETY 5
  • Target Price
  • STOK $27.75
  • GETY $4.35
  • AVG Volume (30 Days)
  • STOK 763.5K
  • GETY 798.8K
  • Earning Date
  • STOK 08-06-2025
  • GETY 08-11-2025
  • Dividend Yield
  • STOK N/A
  • GETY N/A
  • EPS Growth
  • STOK N/A
  • GETY N/A
  • EPS
  • STOK 0.88
  • GETY N/A
  • Revenue
  • STOK $190,908,000.00
  • GETY $941,086,000.00
  • Revenue This Year
  • STOK $378.84
  • GETY $2.71
  • Revenue Next Year
  • STOK N/A
  • GETY $2.74
  • P/E Ratio
  • STOK $14.68
  • GETY N/A
  • Revenue Growth
  • STOK 2333.81
  • GETY 4.20
  • 52 Week Low
  • STOK $5.35
  • GETY $1.25
  • 52 Week High
  • STOK $16.15
  • GETY $4.49
  • Technical
  • Relative Strength Index (RSI)
  • STOK 55.63
  • GETY 48.72
  • Support Level
  • STOK $12.25
  • GETY $1.82
  • Resistance Level
  • STOK $14.99
  • GETY $1.96
  • Average True Range (ATR)
  • STOK 0.83
  • GETY 0.10
  • MACD
  • STOK -0.04
  • GETY 0.00
  • Stochastic Oscillator
  • STOK 36.30
  • GETY 36.05

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About GETY Getty Images Holdings Inc.

Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.

Share on Social Networks: